US FDA approves Lantheus’ new prostate cancer imaging formulation
06/03/2026 21:03
March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings’ LNTH.O prostate cancer imaging agent, aimed at improving scanning access through increased production capacity. (Reporting by Sahil Pandey, Puyaan Singh and Kamal Choudhury in Bengaluru; Editing by Sahal Muhammed) ((Sahil.Pandey@thomsonreuters.com;))
Recent news on Lantheus Holdings
See all newsBrief: Lantheus Receives Complete Response Letter From FDA For Lnth-2501 (Ga 68 Edotreotide)
US FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issues (updated)
US FDA declines to approve Lantheus’ tumor imaging kit
$7 billion could be a 'light' price tag for Lantheus, Truist analysts say
Lantheus falls after report it is considering potential $7 billion sale